BioAge Labs, Inc.
BIOAHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jun 1, 2026
Scan Results
Daily timeframeBioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The $768.6M market capitalization puts BIOA squarely in small-cap range for its industry. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Market Cap
$768.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-8.01
EPS (TTM)
$-2.40
EPS (Fwd)
$-2.16
ROE
-26.0%
ROA
-17.2%
Cash
$383.2M
Total Debt
$4.0M
Free CF
-$58.3M
52W Change
326.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $383.2M in cash comfortably exceeding the $4.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$58.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -26.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, BIOA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BioAge Labs, Inc. and its sector.